Pfizer’s Covid-19 Antiviral Drug Paxlovid May not be as Effective in Vaccinated Adults, Study Shows
Pharmaceutical giant Pfizer has been marketing its Covid-19 antiviral drug as “Paxlovid”, with the drug initially being granted full approval in May 2021 to treat mild-to-moderate cases of the virus in adults at high risk for severe symptoms. The pill was initially made available under emergency use authorization in 2021.
However, a recent study published in the New England Journal of Medicine has shown that Paxlovid may not be as effective in vaccinated adults or those at low risk for severe symptoms. The full study results were published in NEJM on Wednesday, after Pfizer initially released results in 2022.
The findings raise questions about the effectiveness of Paxlovid in certain populations, particularly those who have already been vaccinated against Covid-19. It is recommended that individuals consult with their healthcare providers to determine the best course of treatment for their specific situation.
Despite these new findings, Paxlovid remains an important tool in the fight against Covid-19, particularly for those at high risk for severe symptoms. Pfizer continues to monitor the effectiveness of the drug in different populations and is committed to providing safe and effective treatment options for those affected by the virus.
“Travel aficionado. Incurable bacon specialist. Tv evangelist. Wannabe internet enthusiast. Typical creator.”